Pharmacelera Raises €6 Million to Accelerate U.S. Expansion and Scale Quantum-AI Drug Discovery Platform

New updates have been reported about Pharmacelera.

Pharmacelera has secured €6 million in new funding to accelerate U.S. expansion and enhance its quantum mechanics and AI-based (“QaiM”) drug discovery platform, positioning the company to deepen commercial relationships with major pharma and biotech clients. The round, led by Heran Partners with participation from Clave Capital, Inveready and Bio&Tech Smart Capital, will finance a permanent U.S. team and R&D to extend the platform’s capabilities in priority growth areas.

The Barcelona-based deep tech firm says its QaiM engine can search a vast chemical “exaSpace” of potential molecules, delivering candidates that are up to 10 times better and 75,000 times faster than traditional AI-led approaches, with applications spanning hit identification through lead optimization for small molecules and peptides. Pharmacelera, which has already executed more than 100 projects and counts three large pharma players and multiple biotechs as recurring customers, views this financing and its earlier strategic alliance with General Inception as validation of its model and technology, and expects the expanded platform and U.S. footprint to drive further revenue growth and strengthen its role as an enabling partner in next-generation drug discovery.